FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

AGs Seek FDA Actions on Counterfeit GLP-1 Drugs

A bipartisan coalition of 37 state Attorneys General call on FDA to take enforcement actions against online sellers of counterfeit versions of popular...

latest-news-card-1
Human Drugs

Multiple Violations at Jagsonpal Pharmaceuticals

FDA warns Indias Jagsonpal Pharmaceuticals about CGMP deviations and other violations in its manufacturing of active pharmaceutical ingredients.

latest-news-card-1
Human Drugs

CGMP Deviations at Tyche Industries

FDA warns Indias Tyche Industries about CGMP deviations in its manufacturing of active pharmaceutical ingredients.

latest-news-card-1
Medical Devices

Publish Guidance on Robotic Mastectomy: Petition

Harmed Americans for Reform in Medical Device Safety asks FDA to repost two safety communications and to analyze and post its findings on two studies ...

latest-news-card-1

Top Five 2024 FDA Data Quality Issues

A Med Device Online guest column lists and analyzes FDAs top five data quality citation issues in 2024.

latest-news-card-1
Biologics

GSKs Penmenvy Vaccine for Meningococcal Disease

FDA approves a GSK BLA for Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) for preventing invasive meningococcal disease.

latest-news-card-1
FDA General

Hundreds of FDA Employees Get Termination Letters

The Trump Administration fires hundreds of FDA probationary employees over the weekend as part of its efforts to trim government fat.

latest-news-card-1
Human Drugs

Deciphera Pharma Gets OK for Romvimza

FDA approves a Deciphera Pharmaceuticals NDA for Romvimza (vimseltinib) for treating adult patients with symptomatic tenosynovial giant cell tumors.

latest-news-card-1
Human Drugs

AlgoTx Will Continue ATX01 15% Development

Based on partially successful Phase 2 study results, AlgoTx says it plans to continue developing ATX01 for chemotherapy-induced peripheral neuropathy.

latest-news-card-1
Human Drugs

Gilead Seeks OK for Twice Yearly Lenacapavir

FDA accepts for priority review a Gilead Sciences NDA for lenacapavir for twice-yearly use in preventing HIV as pre-exposure prophylaxis.